BOARD OF DIRECTORS

Gilbert Burgos, MD, MPH

CHAIRMAN
Director of Medical Affairs
Elderplan/Homefirst
Bronx. NY

Elena Rios, MD, MSPH, MACP
PRESIDENT & CEO
National Hispanic Medical Association

Washington, DC Bert Johansson, MD, PhD CHAIRMAN-ELECT

Pediatrician
Pediatric Critical Care
El Paso, TX

Elizabeth Lee-Rey, MD, MPH
TREASURER

Partner
Eastchester Medical Associates, PC
Bronx. NY

Nereida Correa, MD

PAST CHAIRWOMAN Partner Eastchester Medical Associates, PC

Eastchester Medical Associates, PC Bronx, NY **David Hayes Bautista, PhD**

Director, Center on Latino Culture and Health Professor, David Geffen School of Medicine, UCLA Los Angeles, CA

Maria Carrasco, MD, MPH
Regional Physician Lead on Cultural Competence
Kaiser Permanente

Montebello, CA
Ricardo Correa, MD

Director, Endocrinology, Diabetes and Metabolism University of Arizona College of Medicine Phoenix, AZ

Armando De Alba Rosales, MD, MPH
Assistant Dean for DEI
Associate Professor, Dept of Family Medicine
Ohama. NE

Larissa De Sousa President, LMSA MD Candidate

Case Western Reserve University School of Medicine, OH

Alvaro Galvis, MD, PhD
Chair, Council of Young Physicians
Attending Physician
Loma Linda University
San Bernardino, CA

Linda M. Mirdamadi, MD Adjunct Clinical Assistant Professor, Keck School of Medicine

USC Board of Governors Southern CA

Steven Morrin, MD Chair, Council of Residents/Fellows Emergency Medicine Resident

Emergency Medicine Resident Northwell Health, NY Sylvia P. Preciado, MD

Internist
Huntington Hospital
Pasadena, CA

Vice President, The Saucedo Company El Paso, TX

Leonardo Seoane, MD Senior Vice President and CAO, Ochsner Health New Orleans, LA

Brian Ternan
President and CEO, California Health and
Wellness/Health Net, Centene Corporation

Sacramento, CA Claudia H. Zamora, MPA Founder & CEO, Zamora Consulting Group Washington, DC

ADVISORY COUNCIL

Richard H. Carmona, MD, MPH, FACS 17th U.S. Surgeon General (2002-2006) Chief of Health Innovation. Canyon Ranch

Distinguished Professor Mel & Enid Zuckerman College of Public Health MEZCOPH, University of Arizona

> Henry Cisneros Chairman CityView San Antonio, TX

Linda Griego President & CEO Griego Enterprises, Inc. Los Angeles, CA

Los Angeles, CA
Paloma Hernandez, MPH, MS
President & CEO
Urban Health Plan, Inc.
Bronx, NY



May 2, 2024

The Honorable Xavier Becerra Secretary Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201

Dear Secretary Becerra,

We are heartened by the recent news that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Pemgarda, a new Monoclonal antibody (mAB) treatment. This marks a significant advancement in our ongoing battle against COVID-19. We extend our gratitude for the administration's dedication to advancing this vital prevention and treatment option and urge its swift introduction and integration into the marketplace.

While Pemgarda's approval represents a crucial milestone, it is just one facet of our broader challenge. The availability of safe and effective medicine on the market can only truly benefit those in need if it is accessible and affordable. As a coalition encompassing minority health organizations, labor unions, and consumer advocates, we emphasize ensuring the accessibility and affordability of all safe and effective COVID-19 prevention and treatment options for every American.

We commend your past efforts in advocating for increased access to affordable life-saving medications, notably demonstrated by your September 2023 letter to healthcare payers urging coverage of the updated COVID-19 vaccines without cost-sharing. We strongly encourage you to extend similar guidance for Pemgarda and all approved COVID-19 therapies.

Despite the efficacy of existing COVID-19 therapies, relying solely on antivirals and vaccines falls short of safeguarding the estimated seven million immunocompromised individuals in the U.S. As you are aware, these vulnerable patients—especially those facing barriers to accessing or affording newly approved medications and therapies—do not reap the same benefits from antivirals and vaccines as individuals with healthy immune systems.

Your September letter underscored the paramount importance of reducing barriers to coverage and urged consideration of all avenues to achieve this goal. We urge you to apply this same urgency to all COVID-19 therapies. Building upon your call to ensure equitable access to all safe and effective treatments, including mABs, is imperative.

In closing, we appeal to your continued leadership and advocacy to prioritize the accessibility and affordability of safe and effective COVID-19 therapies for all Americans. By working together, we can ensure that no individual is left behind in our collective efforts to overcome this pandemic.

Thank you for your attention to this critical matter. Sincerely,

Elena Rios, MD, MSPH, MACP

President & CEO

A. Phillip Randolph Institute

Asian & Pacific Islander American Forum

Alliance for Retired Americans

Black Women's Health Imperative

Consumer Action

Egality Science

Hispanic Federation

Latin Council for Latin American Advancement

Latino Caucus for Public Health

Latinx Medical and Health Society

Long Covid Alliance

Long Covid Families

Long Covid Justice

National Association of Latino Healthcare Executives

National Consumers League

National Hispanic Council on Aging

National Association of Hispanic Nurses

National Latino Behavioral Health Association (new)

Rare Disease Diversity Coalition

The Dick Gregory Society

The Latino Coalition









- SCIENCES -

consumeraction





























National Latino Behavioral Health Association

